UBS analyst Danielle Antalffy lowered the firm’s price target on Inspire Medical (INSP) to $230 from $270 and keeps a Buy rating on the shares. A slew of headwinds drove the guidance revision lower by more than expected, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Hold from Buy at Truist
- Inspire Medical downgraded to Neutral from Overweight at JPMorgan
- Inspire Medical downgraded to Sector Weight from Overweight at KeyBanc
- Inspire Medical Systems Reports Q2 2025 Financials
- Closing Bell Movers: Palantir hits record highs on beat and raise